 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
209 News |  |
| 1234» |
- | Natacyn (natamycin) / Novartis, Jublia (efinaconazole) / Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: Antifungal susceptibility, clinical findings, and biofilm resistance of Fusarium species causing keratitis: a challenge for disease control. (Pubmed Central) - Mar 6, 2025
This study highlights the importance of mycological diagnosis and the antifungal susceptibility testing in the clinical management of FK. The ability of Fusarium to form antifungal tolerant biofilms poses a challenge to clinicians and urges the development of new antibiofilm therapeutics.
- || Luzu (luliconazole) / Bausch Health
Review, Journal: Eumycetoma Caused by Aspergillus terreus: A Case Report and Literature Review. (Pubmed Central) - Mar 5, 2025
We applied a combination treatment consisting of itraconazole with topical luliconazole cream and radiofrequency microneedling, and this was followed by significant regression of the lesion. In addition, we reviewed the current literature to summarize the epidemiological characteristics of mycetoma in mainland China and cases of eumycetoma caused by A. terreus worldwide.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Novel in vivo observations of luliconazole 5% nail solution for onychomycosis: an ultrastructural study. (Pubmed Central) - Mar 4, 2025
Intracytoplasmic degeneration (type 1 degeneration) was observed in tinea pedis scales treated with topical KCZ. We confirmed that topical LLCZ 5% nail solution had acting points on the plasma membrane, cell wall and cytoplasm of dermatophyte hyphae and that various degrees of morphological changes in lesional nails of tinea unguium occurred during treatment with topical LLCZ 5% nail solution.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Luliconazole-niacinamide lipid nanocarrier laden gel for enhanced treatment of vaginal candidiasis: in vitro, ex vivo, in silico and preclinical insights. (Pubmed Central) - Feb 21, 2025
In vivo antifungal activity showed that the optimized LZNMLNs-gel completely treated the infection on the 7th day of treatment in an induced rabbit model, compared to the commercial gel (Candid V gel, 10 days). Based the findings, it can be concluded that LN-laden gel is an alternative carrier for improvement of the topical delivery of drugs for the treatment of vaginal candidiasis.
- | Luzu (luliconazole) / Bausch Health
Journal: Crystal structure of luliconazole. (Pubmed Central) - Jan 12, 2025
In the crystal packing of luliconazole, only two inter-molecular C-H?N hydrogen bonds are observed. Hirshfeld surface analysis reveals that the most dominant contacts are H?N/N?H, H?Cl/Cl?H, H?H and C?H/H?C.
- | Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
Journal: Case of tinea corporis caused by a terbinafine-sensitive Trichophyton indotineae strain in a Vietnamese worker in Japan. (Pubmed Central) - Jan 6, 2025
The reason for recalcitrance in this case, despite the isolate's sensitivity to antimycotics, was unclear. Possible factors include insufficient use of the antimycotics, incomplete removal of abundantly produced conidia from the lesions, the patient's environment, and a language gap between the patient and physician hindering communication.
- | Luzu (luliconazole) / Bausch Health
Journal: Deep Dermal Dilemma: A Case Report on Majocchi's Granuloma After Topical Steroid Use. (Pubmed Central) - Nov 19, 2024
Fungal culture was performed, which showed growth of Trichophyton rubrum. The patient was started on oral terbinafine 250 mg once daily and topical luliconazole cream twice daily topical application, which resolved the lesions in three weeks, but the patient was advised to continue the treatment for a total duration of two months.
- | Jublia (efinaconazole) / Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: Development of treatment strategies by comparing the minimum inhibitory concentrations and minimum fungicidal concentrations of azole drugs in dermatophytes. (Pubmed Central) - Nov 2, 2024
To assess the MICs of ITCZ, ravuconazole (RVCZ), efinaconazole (EFCZ), and luliconazole (LUCZ) in the isolates, broth microdilution assays were performed based on the Clinical and Laboratory Standards Institute M38-A2 guidelines with modifications...The MFCs in the dermatophytes were 1 to >32?mg/L for ITCZ, 0.06 to >32?mg/L for RVCZ, <0.03 to 4?mg/L for EFCZ, and <0.03 to 2?mg/L for LUCZ. If the drug susceptibility test shows that the fungi are resistant to the drug, the treatment can be changed to a susceptible drug in advance, or if the fungi are low-susceptible, the treatment can be done with the recognition that it may require a longer treatment period than usual.
- | Luzu (luliconazole) / Bausch Health
Journal: Prolonged Skin Retention of Luliconazole from SLNs Based Topical Gel Formulation Contributing to Ameliorated Antifungal Activity. (Pubmed Central) - Oct 2, 2024
If the drug susceptibility test shows that the fungi are resistant to the drug, the treatment can be changed to a susceptible drug in advance, or if the fungi are low-susceptible, the treatment can be done with the recognition that it may require a longer treatment period than usual. The
- | Journal: First Confirmed Description of Acremonium egyptiacum from Greece and Molecular Identification of Acremonium and Acremonium-like Clinical Isolates. (Pubmed Central) - Sep 27, 2024
Amphotericin B, itraconazole, posaconazole, voriconazole, terbinafine, amorolfine, and griseofulvin MICs were overall high (GM 12.79-29.49 ?g/mL)...Antifungal susceptibility of the three different A. egyptiacum genotypes was homogeneous. Overall, the high MICs recorded for all systemically administered drugs, and for some topical antifungals against the tested A. egyptiacum and other acremonium-like clinical isolates, justify the routine susceptibility testing of clinical isolates.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Polymeric micelle gel with luliconazole: in vivo efficacy against cutaneous candidiasis in Wistar rats. (Pubmed Central) - Sep 24, 2024
Finally, in vivo fungal scaling and histopathological studies indicated a reduction in fungal infection in Wistar rat skin after treatment. The obtained results suggested that LUL-PM can serve as a promising formulation to enhance luliconazole antifungal activity and increase patient compliance.
- | Jublia (efinaconazole) / Bausch Health, Luzu (luliconazole) / Bausch Health, Nailin (fosravuconazole) / DNDi, Eisai
Journal, Claims database: Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study. (Pubmed Central) - Sep 2, 2024
The substantial increase in medical costs also highlights the economic burden of onychomycosis and the need for cost-effective treatment strategies. This study provides valuable insights into the real-world prescription trends and medical costs of onychomycosis treatment in Japan, suggesting an opportunity to assess potential gaps between guideline recommendations and clinical practice.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Prolonged retention of luliconazole nanofibers for topical mycotic condition: development, in vitro characterization and antifungal activity against Candida albicans. (Pubmed Central) - Aug 8, 2024
This study provides valuable insights into the real-world prescription trends and medical costs of onychomycosis treatment in Japan, suggesting an opportunity to assess potential gaps between guideline recommendations and clinical practice. In antifungal activity using Candida albicans, the Luz-PVA nanofibers showed a greater zone of inhibition (30.55?
- Luzu (luliconazole) / Bausch Health
Disseminated Fusarium solani infection presenting as pyoderma gangrenosum (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4056;
In antifungal activity using Candida albicans, the Luz-PVA nanofibers showed a greater zone of inhibition (30.55? The patient
- Luzu (luliconazole) / Bausch Health
A Clinico-mycological, immunological and aerobiological study of resistant/recalcitrant dermatophytosis in adults in a tertiary care centre (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3922;
The patient Objective
- Luzu (luliconazole) / Bausch Health
Comparing emollient use with topical luliconazole (azole)in the maintenance of remission of chronic and recurrentdermatophytosis. An open-label, randomized prospectiveactive-controlled non-inferiority study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3860;
Objective The present study concludes that the efficacy of emollient was not inferior to topical luliconazole for maintaining remission in chronic and recurrent dermatophytosis.
- | epetraborole (AN3365) / AN2 Therap, Luzu (luliconazole) / Bausch Health, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Preclinical, Journal: Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro. (Pubmed Central) - Jul 23, 2024
MMV1580854, MMV1579788, eravacycline and epetraborole inhibited both the bacterial test isolates...Five compounds from MMV Pandemic Box were found to be inhibiting colistin and ceftazidime resistant A. baumannii clinical isolate, also against colistin and ?-lactam resistant P. aeruginosa clinical isolate...MMV1782110, Eberconazole, amorolfine and luliconazole exhibited potent anti-fungal activity. Further investigations are warranted to identify the targets and mechanism.
- | Journal: Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals. (Pubmed Central) - Jul 3, 2024
In comparison to A. fumigatus, azole and amphotericin B MICs were slightly elevated for some strains. AFST with luliconazole and olorofim, here reported for the first time, displayed the highest in vitro activity, making these antifungals interesting alternative drugs but clinical studies are warranted for future therapeutic use.
- || Jublia (efinaconazole) / Kaken Pharma, Bausch Health, Luzu (luliconazole) / Bausch Health, Nailin (fosravuconazole) / DNDi, Eisai, Sato Pharma
Review, Journal: Dermatophytomas in Onychomycosis: A Scoping Review of Prevalence, Diagnosis, and Treatment. (Pubmed Central) - May 16, 2024
More clinical research and physician education are needed. Although dermatophytomas have historically been considered difficult to treat, the efficacy data gathered in this scoping review have demonstrated that newer topical treatments are effective, as are oral antifungals in combination with chemical or surgical methods.
- | Preclinical, Journal: Identifying novel aryl hydrocarbon receptor (AhR) modulators from clinically approved drugs: In silico screening and In vitro validation. (Pubmed Central) - Apr 1, 2024
Importantly, these findings hold immense therapeutic potential for addressing AhR-associated disorders. Consequently, it offers compelling prospects for innovative interventions through drug repurposing.
- | Luzu (luliconazole) / Bausch Health
Journal: Fabrication of gelatin coated polycaprolactone nanofiber scaffolds co-loaded with luliconazole and naringenin for treatment of Candida infected diabetic wounds. (Pubmed Central) - Mar 11, 2024
Additionally, a higher blood flow and rapid re-epithelialization of wound tissue in the treatment group corroborated the results obtained in the wound closure study. Overall, the developed dual-drug-loaded electrospun nanofiber mats have good compatibility, surface properties, and excellent wound healing potential, which can provide an extra edge in the management of complex diabetic wounds.
- | Luzu (luliconazole) / Bausch Health
Journal: Sulconazole induces pyroptosis promoted by interferon-? in monocyte/macrophage lineage cells. (Pubmed Central) - Feb 28, 2024
Overall, the developed dual-drug-loaded electrospun nanofiber mats have good compatibility, surface properties, and excellent wound healing potential, which can provide an extra edge in the management of complex diabetic wounds. All six imidazole derivatives examined, namely ketoconazole, sulconazole, isoconazole, luliconazole, clotrimazole, and bifonazole, reduced the expression levels of inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-?, after induction by lipopolysaccharide (LPS) in RAW264.7
- | Luzu (luliconazole) / Bausch Health
Journal: Formulation and characterization of polyvinyl alcohol/chitosan composite nanofiber co-loaded with silver nanoparticle & luliconazole encapsulated poly lactic-co-glycolic acid nanoparticle for treatment of diabetic foot ulcer. (Pubmed Central) - Feb 8, 2024
In-vitro studies confirmed the biocompatibility and enhanced proliferation of Human keratinocytes cells (HaCaT). In-vivo studies showed accelerated wound closure by providing ant-infective action, supporting cellular proliferation and improving blood flow, all collectively contributing in expediated wound healing.
- | Luzu (luliconazole) / Bausch Health
Journal, Head-to-Head: Comparing emollient use with topical luliconazole (azole) in the maintenance of remission of chronic and recurrent dermatophytosis. An open-label, randomized prospective active-controlled non-inferiority study. (Pubmed Central) - Jan 30, 2024
In-vivo studies showed accelerated wound closure by providing ant-infective action, supporting cellular proliferation and improving blood flow, all collectively contributing in expediated wound healing. The present study concludes that the efficacy of emollient was not inferior to topical luliconazole for maintaining remission in chronic and recurrent dermatophytosis.
- | Luzu (luliconazole) / Bausch Health
Journal: Quality by Design Assisted Development of Luliconazole Transethosomes in Gel for the Management of Candida albicans Infection. (Pubmed Central) - Jan 19, 2024
The results observed from the skin permeation and skin deposition profile ensure that the prepared novel LUL-loaded TE system had a higher permeation rate and increased retention time compared with LUL-CHG. The hydrogel incorporated with LUL could be a novel approach with safe and effective fungal treatment.
- | Luzu (luliconazole) / Bausch Health
Journal: Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis: A randomised control trial. (Pubmed Central) - Jan 16, 2024
The hydrogel incorporated with LUL could be a novel approach with safe and effective fungal treatment. Our study shows a similar cure rate and relapse rate for patients receiving topical Luliconazole versus topical bland emollient as an adjuvant to the systemic itraconazole regime.
- || Luzu (luliconazole) / Bausch Health
Review, Journal: Possibly the first case of onychomycosis by Fusarium lactis: Case presentation and literature review of onychomycosis by Fusarium species. (Pubmed Central) - Dec 4, 2023
Since there has been an increase in instances of molecular determination of Fusarium spp., it is deemed necessary to clarify its clinical and fungal nature. Due to its characteristic drug sensitivity and temperature-sensitive nature, new treatments are expected to be developed.
- | itraconazole / Generic mfg.
Preclinical, Journal: In vitro Azole Susceptibility Testing of Japanese Isolates of Itraconazole-Resistant Dermatophytes. (Pubmed Central) - Nov 30, 2023
In all isolates, the minimum inhibitory concentrations (MICs) were > 32 mg/l for ITCZ, < 0.03 to 0.5 mg/l for ravuconazole (RVCZ), and < 0.03 mg/l for efinaconazole (EFCZ), luliconazole (LUCZ), and terbinafine (TRBF). Thus, in tinea unguium cases with ITCZ-resistant strains, treatment should be switched to TRBF or other azoles with a stronger antifungal efficacy, such as EFCZ, LUCZ, or RVCZ, and treatment must continue until the infectious organisms are completely eliminated.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Phase-Dependent Differential In Vitro and Ex Vivo Susceptibility of Aspergillus flavus and Fusarium keratoplasticum to Azole Antifungals. (Pubmed Central) - Oct 27, 2023
We conclude that traditional antifungal susceptibility testing with conidial suspensions does not correlate with fungal susceptibility in cultures of a more advanced developmental phase. A revised method of antifungal susceptibility testing that evaluates hyphal susceptibility may better predict fungal response in the clinical setting where treatment is often delayed until days after the initial insult.
- | Luzu (luliconazole) / Bausch Health
Journal: A new record of Scedosporium dehoogii isolated from paddy field soil in Iran: Phylogeny and antifungal susceptibility profiles. (Pubmed Central) - Sep 22, 2023
Based on the findings, molecular identification was essential for distinguishing the species of S. dehoogii. Remarkably, luliconazole showed potent activity against this strain.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Development of Soft Luliconazole Invasomes Gel for Effective Transdermal Delivery: Optimization to In-Vivo Antifungal Activity. (Pubmed Central) - Aug 25, 2023
albicans) in the infected rats. The finding concluded that IVS gel is a good carrier and an attractive approach for the enhancement of topical delivery of LZ to treat the fungal infection.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Antifungal Efficacy of Luliconazole in an Experimental Rabbit Model of Fungal Keratitis Caused by Fusarium solani. (Pubmed Central) - Aug 21, 2023
In conclusion, luliconazole demonstrated therapeutic efficacy comparable to that of natamycin in treating experimental fungal keratitis. This suggests that luliconazole can be a novel therapeutic agent for human fungal keratitis.
- | Luzu (luliconazole) / Bausch Health
Journal: Aspergillus welwitschiae; a predominant otomycosis agent, new epidemiological and antifungal susceptibility data from Iran. (Pubmed Central) - Jul 10, 2023
Also, 3.2% of A. tubingensis strains were non-wild type against amphotericin B. All A. welwitschiae were included in the A. niger/A. welwitschiae clade, associated with different clinical and environmental species from different countries.
- Zalain (sertaconazole) / Elder Pharma, Jublia (efinaconazole) / Kaken Pharma, Bausch Health, Almirall, Luzu (luliconazole) / Bausch Health
Erroneous Use of Dithranol, Boric Acid and Salicylic Acid in Patients with Superficial Fungal Infection: A Case Series () - Jul 3, 2023 - Abstract #WCD2023WCD_7469;
He had consulted ophthalmologist for ocular reaction. KEY MESSAGE: Ointments containing Boric Acid (1%), Dithranol (0.1%), and Salicylic Acid (2%) (BADSA) should not be used in patients with SFI
- Luzu (luliconazole) / Bausch Health
Clinico epidemiological and mycological study of Dermatophytosis with sensitivity testing () - Jul 3, 2023 - Abstract #WCD2023WCD_7411;
KEY MESSAGE: Ointments containing Boric Acid (1%), Dithranol (0.1%), and Salicylic Acid (2%) (BADSA) should not be used in patients with SFI Dermatophytosis is commonly encountered in young and middle aged individuals with higher incidence among males.In our study Tinea corporis was the commonest presentation with most common agent isolated being Trichophyton rubrum.Among the 5 antifungal agents tested, Luliconazole has the lowest MIC range whereas Fluconazole has the highest range.This implies that Luliconazole is more potent than other agents
- Luzu (luliconazole) / Bausch Health
Carbon Dioxide Laser Plus Topical 5% Luliconazole: A Better Combination Therapeutic Modality for Onychomycosis () - Jul 3, 2023 - Abstract #WCD2023WCD_4125;
Dermatophytosis is commonly encountered in young and middle aged individuals with higher incidence among males.In our study Tinea corporis was the commonest presentation with most common agent isolated being Trichophyton rubrum.Among the 5 antifungal agents tested, Luliconazole has the lowest MIC range whereas Fluconazole has the highest range.This implies that Luliconazole is more potent than other agents Fractional CO2 laser combined with topical luliconazole 5% lotion is a safe and effective treatment for onychomycosis especially in those who have contraindications to oral antifungals
- clobetasol propionate topical / Generic mfg.
The economic burden of topical corticosteroid use in dermatophytosis: A cost of illness analysis of steroid modified vs steroid-na () - Jul 3, 2023 - Abstract #WCD2023WCD_4022;
A substantial financial burden is posed by the current epidemic/endemic of chronic recurrent dermatophytosis in India. Those who have been previously treated with topical corticosteroids seem to incur significantly higher expenditures (40% more) when compared to steroid- na
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: In Vitro and In Vivo Effect of the Imidazole Luliconazole against Lomentospora prolificans and Scedosporium spp. (Pubmed Central) - Jun 19, 2023
These data reveal the previously unknown inhibitory effect of LLCZ against L. prolificans and its antibiofilm effect in Scedosporium spp. It represents an extension of the literature regarding azole-resistant fungi and could potentially lead to the development of future treatment strategies against these opportunistic fungal pathogens.
- | Luzu (luliconazole) / Bausch Health
Journal, Real-world evidence, Real-world: Management of Dermatophytosis: Real-World Indian Perspective. (Pubmed Central) - Jun 2, 2023
Additionally, 62% advise liver function tests (LFTs) at the initiation of therapy, whereas 72% advise monitoring adverse effects due to systemic antifungal drugs during treatment. Combination therapy stood out as the need of the hour in the current menace of dermatophytosis with timely monitoring of laboratory tests for adverse events due to the use of systemic antifungals for a longer duration.
- | Jublia (efinaconazole) / Kaken Pharma, Bausch Health, Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
Journal: High Diversity of Fusarium Species in Onychomycosis: Clinical Presentations, Molecular Identification, and Antifungal Susceptibility. (Pubmed Central) - May 26, 2023
Fusarium onychomycosis has clinical and pathological features distinct from those of dermatophyte onychomycosis. Thus, careful diagnosis and proper pathogen identification are essential in the management of NDM onychomycosis caused by Fusarium sp.
- | Luzu (luliconazole) / Bausch Health
Journal: Circular dichroism assessment of an imidazole antifungal drug with plant based silver nanoparticles: Quantitative and DFT analysis. (Pubmed Central) - May 1, 2023
The methods were used in dosage forms that produced a relative standard deviation of less than 2% and the true bias (? and ?) within
- || Luzu (luliconazole) / Bausch Health
Retrospective data, Review, Journal: Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 24, 2023
The lowest resistance levels among azoles were observed in luliconazole with a frequency of 0% and voriconazole of 3.94%. Due to the emergence of multi-drug resistant C. albicans, rational drug prescription based on the anti-fungal stewardship strategy and therapeutic drug monitoring is warranted.
- | Luzu (luliconazole) / Bausch Health
Journal: Novel Luliconazole Spanlastic Nanocarriers: Development and Characterisation. (Pubmed Central) - Mar 27, 2023
Due to the emergence of multi-drug resistant C. albicans, rational drug prescription based on the anti-fungal stewardship strategy and therapeutic drug monitoring is warranted. Collectively, the results revealed that spanlastics could be a potential nanocarrier for wellcontrolled delivery and for targeting deeper skin layers, thus providing new opportunities for dermal treatment.
- | Luzu (luliconazole) / Bausch Health
Journal: Epidemiological study of antifungal-resistant dermatophytes isolated from Japanese patients. (Pubmed Central) - Mar 21, 2023
We also examined for the first time the epidemiology of ITZ-resistant T. rubrum in Japanese patients. Although the number of ITZ-resistant strains was not large, the results confirmed that ITZ-resistant T. rubrum strains do exist in Japanese patients.
- || Luzu (luliconazole) / Bausch Health
To jest, chyba naj lepsze rozwiązanie!!🔥👅💓❤️🌹🌈 Ty dobrze mnie Znasz!! Ja dopiero będę poznawał!!💓🌹!!! Będzie więcej luzu między nami!!🌹💓🌈❤️👅🔥 !!! (Twitter) - Feb 28, 2023
- | Luzu (luliconazole) / Bausch Health, Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
Preclinical, Journal: Comparison of in vitro activities of newer triazoles and classic antifungal agents against dermatophyte species isolated from Iranian University Hospitals: a multi-central study. (Pubmed Central) - Feb 27, 2023
Trichophyton mentagrophytes, Trichophyton interdigitale, and Trichophyton rubrum were the most common fungal species isolated from the patients. luliconazole, terbinafine, and isavuconazole in vitro were revealed to be the most effective antifungal agents against all dermatophyte isolates.
- Luzu (luliconazole) / Bausch Health
The imidazole luliconazole is active against Lomentospora prolificans and Scedosporium spp. in vitro and in vivo (D / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2826;
- | Luzu (luliconazole) / Bausch Health
Journal: The Spray-Dried Alginate/Gelatin Microparticles with Luliconazole as Mucoadhesive Drug Delivery System. (Pubmed Central) - Jan 9, 2023
It was shown that the gelatin addition affected the particles size, improved encapsulation efficiency and mucoadhesiveness, and prolonged the drug release. Moreover, gelatin addition to the formulations improved the antifungal effect against Candida species.
- | ketoconazole / Generic mfg.
Journal: Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study). (Pubmed Central) - Jan 6, 2023
The mean Scalpdex-23 score at week four was reduced by 35.7% and 21.1% in Lulican™ and ketoconazole groups, respectively (p<0.05). Conclusion While both treatments were successful in alleviating SD symptoms and were well tolerated, Lulican™ stood out as a preferred treatment option due to better quality of life (QoL) improvement in SD.
- | Jublia (efinaconazole) / Kaken, Bausch Health
Preclinical, Journal: In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasizing on the potent inhibitory effect of efinaconazole compared to other drugs. (Pubmed Central) - Dec 1, 2022
Efinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis.